Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., As Chief Medical Officer

WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc., today announced the appointment of Leila Alland, M.D. to the position of Chief Medical Officer. Dr. Alland brings more than 15 years of pharmaceutical drug development experience with a focus on oncology including leadership roles in clinical development at AstraZeneca and Bristol-Myers Squibb.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.